4162 On Other Exchanges
Symbol
Exchange
4162 is not on other exchanges.

pharmaengine inc (4162) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMAENGINE INC (4162)

Related News

No related news articles were found.

pharmaengine inc (4162) Related Businessweek News

No Related Businessweek News Found

pharmaengine inc (4162) Details

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs to treat cancer and Asian prevalent diseases in Taiwan. The company licenses in drug candidates ranging from preclinical to clinical stages. It is developing ONIVYDE, a liposome encapsulation of irinotecan for target indications, including pancreatic, gastric, colorectal, breast, and brain cancers, as well as Ewing’s sarcoma; PEP503, a nanoparticle formulation of hafnium oxide for indications comprising head and neck, liver, rectal, and prostate cancers, as well as soft tissue sarcoma; and PEP06 for solid tumors. The company has collaborations with Merrimack Pharmaceuticals, Inc.; Nanobiotix S.A.; and Guangzhou BeBetter Medicine Technology Co., Ltd. PharmaEngine, Inc. was founded in 2003 and is based in Taipei, Taiwan.

Founded in 2003

pharmaengine inc (4162) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pharmaengine inc
PharmaEngine Inc. Presents at Hong Kong and China Corporate Day (Theme: Healthcare), Dec-07-2016 10:00 AM

PharmaEngine Inc. Presents at Hong Kong and China Corporate Day (Theme: Healthcare), Dec-07-2016 10:00 AM. Venue: Mandarin Oriental Hong Kong, Hong Kong, China. Speakers: Grace Yeh, Founder and President & Chief Executive Officer.

Nanobiotix' Partner, PharmaEngine Launches New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia

NANOBIOTIX announced that its partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product. PharmaEngine has broadened its development plan for NBTXR3 by launching this new trial in Asia targeting a new and larger head and neck cancer patient population. This follows the successful results from the European Phase I/II trial in patients with head and neck cancers presented in July 2016 by Nanobiotix demonstrating promising signs of tumor volume response and excellent signs of safety. NBTXR3 is now addressing a wide range of head and neck cancers patients. The study in Asia by PharmaEngine addresses patients receiving chemotherapy (cisplatin) plus radiotherapy whereas the study in Europe by Nanobiotix covers patients which are not eligible for chemotherapy plus radiotherapy and only receive radiotherapy. Head and neck cancers include cancers of the oral cavity, tongue and oropharynx. These cancers are a major concern for public health, with a high worldwide prevalence, particularly in Asia, where the patient population is expanding. This joint approach by Nanobiotix and PharmaEngine supports the preparation of a development plan for head and neck cancers registration studies with NBTXR3 potentially in Europe, in the US and in Asia. Nanobiotix will provide this in 2017.

PharmaEngine Inc. Announces Initiation of Phase 1b/2 Trial of PEP503 (NBTXR3) in Head and Neck Cancer

PharmaEngine Inc. announced that the first patient has been dosed in a phase 1b/2 trial of PEP503 (NBTXR3) of head and neck squamous cell carcinoma (HNSCC) at Keelung Chang Gung Memorial Hospital (Lovers Lake Branch) in Keelung, Taiwan. The Principal Investigator is Prof. Cheng-Hsu Wang, M.D. This prospective, open-label, single arm, non-randomized study (PEP503-HN-1002) of PEP503 in patients with HNSCC is being conducted in Taiwan by PharmaEngine. The primary objectives of this study are to determine the optimal dose, safety and preliminary efficacy of PEP503 through intra-tumor injection in combination with the standard treatment of concurrent chemoradiotherapy (CCRT) in SCC of oral cavity. A maximum of 42 patients may be enrolled in the phase 1b/2 study. The company's partner, Nanobiotix, is conducting a head and neck cancer study (NBTXR3 Study-102) of NBTXR3 (PEP503) in combination with radiation in elderly patients with SCC of oral cavity and oropharynx, who are not suitable for chemotherapy plus radiotherapy. These two studies will then identify the optimal doses for patients who can or cannot receive chemotherapy with radiotherapy plus NBTXR3 (PEP503).

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4162 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4162.
View Industry Companies
 

Industry Analysis

4162

Industry Average

Valuation 4162 Industry Range
Price/Earnings 100.0x
Price/Sales 77.6x
Price/Book 8.0x
Price/Cash Flow 618.2x
TEV/Sales 68.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact PHARMAENGINE INC, please visit www.pharmaengine.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.